Dataset opportunity
Wm Uk — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Wm Uk, usable for Diagnostic AI and Computer Vision.
Score
59.1
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
42%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Rare Disease Diagnostics Market = USD 1.36 billion in 2024, projected to reach USD 22.12 billion by 2035, with a CAGR of 27.8% (2025-2035). The broader Global AI in Medical Imaging Market = USD 1.70 Billion in 2024, expected to reach US$ 16.88 Billion by 2034, growing at a CAGR of 25.8% (2025-2034).
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📝Published article
WM Research & Data page emphasizes data's core role in charity's work
source ↗ - ✨Signal
Established the Rory Morrison WMUK Registry to collect clinical patient data
source ↗ - 📝Published article
Published the First UK Waldenström's Macroglobulinaemia Registry Report in collaboration with Dendrite Clinical Systems
source ↗ - 🧑💻Hiring a data role
Previously hired for 'Information and Data Administrator' role to maintain accurate and clean data
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
Low (commodity)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Wm Uk possesses a Medical Imaging Dataset comprising clinical patient data specifically for Waldenstrom's Macroglobulinaemia, a rare blood cancer. This unique dataset, despite being collected between 2017 and 2025 and acknowledged as incomplete and not representative of all WM patients, is highly valuable for training Diagnostic AI models.
The market for AI in rare disease diagnostics is experiencing high growth, valued at USD 1.36 billion in 2024 and projected to reach USD 22.12 billion by 2035 with a CAGR of 27.8%. While access requires navigating strict ethical and GDPR compliance for sensitive health data and data monetization might conflict with the charity's mission, the data's rarity and potential for advancing diagnosis in a critical area make it exceptionally valuable. ⚠ Diligence (valuable data, access to negotiate): Data is clinical patient data for a rare blood cancer (Waldenstrom's Macroglobulinaemia).; Data collection for the Rory Morrison WMUK Registry ran from 2017 to 2025; the charity found the data to be incomplete and not representative of all WM patients when they took over in 2023.; Access would require navigating strict ethical and GDPR compliance for sensitive health data.; As a charity, data monetization might conflict with its mission, requiring careful structuring. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
- Dataset Specificity66
dominant 'medical_records', sector healthcare, 1 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity34
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume46
2 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value64
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
The AI in medical imaging market, which relies heavily on medical imaging datasets for diagnostic AI, is projected to grow at a Compound Annual Growth Rate (CAGR) of 34.8% from 2025 to 2034, indicating extremely high and rapidly increasing
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility32
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength50
2 evidence types, 2 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation95
4 data-appetite signals (3 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - ICP Audit75
⚠ review — WMUK is a charity focused on Waldenstrom's macroglobulinaemia, collecting clinical data for research and advocacy, but explicitly states it does not sell or share data for commercial purposes, making it unsuitable for a data marketplace seeking data sellers. Issues: The company is a registered charity, not a commercial entity.; WMUK's privacy policy explicitly states they 'will never share, sell or swap your details with any third parties for the purposes of their own marketing or com
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Wm Uk holds multimodal and image-based data centered on Waldenström's Macroglobulinaemia, a rare condition, evidenced by a globally unique patient registry. This dataset is exceptionally valuable for Medical-AI and diagnostic-imaging companies developing Diagnostic AI solutions. With the AI in Rare Disease Diagnostics market projected to reach over $22 billion by 2035, this opportunity provides a critical foundation for advancing precision diagnostics in a rapidly growing and underserved segment.
Medical records / imaging
This evidence confirms an image-based registry of clinical data for Waldenström's Macroglobulinaemia patients, offering crucial training material for diagnostic AI.
Data catalog / marketplace
This evidence highlights a multimodal dataset, notably the "First UK Waldenström's Macroglobulinaemia Registry Report," a globally unique compilation, offering a foundational resource for AI development in rare disease diagnostics.
Deal room
Deal Room — Wm Uk — Medical Imaging Dataset Opportunity
Medical Imaging Dataset (Image, healthcare). Best AI use-case: Diagnostic AI. Target buyers: Medical-AI & diagnostic-imaging companies. Market: Global AI in Rare Disease Diagnostics Market = USD 1.36 billion in 2024, projected to reach USD 22.12 billion by 2035, with a CAGR of 27.8% (2025-2035). The broader Global AI in Medical Imaging Market = USD 1.70 Billion in 2024, expected to reach US$ 16.88 Billion by 2034, growing at a CAGR of 25.8% (2025-2034).. Rarity: Low (commodity); accessibility: Restricted. Key risk: Owned by the company — GDPR-sensitive (PII review). Recommended deal structure: Data Sharing Agreement. Investment score 59.1/100.
Buyer persona
Medical-AI & diagnostic-imaging companies
The type of company or team most likely to buy or use this dataset — the target on the demand side.Market
Global AI in Rare Disease Diagnostics Market = USD 1.36 billion in 2024, projected to reach USD 22.12 billion by 2035, with a CAGR of 27.8% (2025-2035). The broader Global AI in Medical Imaging Market = USD 1.70 Billion in 2024, expected to reach US$ 16.88 Billion by 2034, growing at a CAGR of 25.8% (2025-2034).
A rough read on demand and price band for this data, from market signals ($ = niche, $$$ = high AI-buyer demand).Risk
Owned by the company — GDPR-sensitive (PII review)
The main legal and compliance constraints on using or transferring this data — PII/GDPR, licensing rights, regulatory limits.Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Coverage
Scanned sources
Deliverable
Premium dataset report
Wm Uk Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Rare Disease Diagnostics Market = USD 1.36 billion in 2024, projected to reach USD 22.12 billion by 2035, with a CAGR of 27.8% (2025-2035). The broader Global AI in Medical Imaging Market = USD 1.70 Billion in 2024, expected to reach US$ 16.88 Billion by 2034, growing at a CAGR of 25.8% (2025-2034).. Investment score 59.1/100 (confidence 0.42). Recommended action: Data Sharing Agreement.